COVID-19

Genitourinary Cancers

Questions discussed in this category

What oral alternatives would you recommend as opposed to injectable GnRH agonists for those who do not wish to come to clinic due to COVID-19?

This applies to both de novo cases and patients who have previously received injectable agents.

1 Answer available

How would you boost a high-risk prostate cancer patient who received standard fractionation treatment and is not able to get LDR boost given COVID-19?

Would you use SBRT, hypofractionated or standard fractionated boost?

3 Answers available

What is the longest acceptable interval between radical orchiectomy and adjuvant BEP for Stage IIB/III pure seminoma in the age of COVID-19?

2 Answers available

Is there any consensus or guidance on how to manage germ cell tumor patients in the COVID-19 era?

1 Answer available

What scenarios, if any, are you delaying adjuvant chemotherapy in light of the COVID-19 outbreak?

1 Answer available

Have your treatment recommendations for urothelial cancer patients changed given the ongoing COVID19 pandemic?

Would you forego neoadjuvant chemotherapy? Are you using growth factor support differently? Any changes to immunotherapy? Other considerations?

2 Answers available

Papers discussed in this category

JAMA Netw Open, 2020 Feb 05

Evaluation of the Association of Perioperative UGT1A1 Genotype-Dosed gFOLFIRINOX With Margin-Negative Resection Rates and Pathologic Response Grades Among Patients With Locally Advanced Gastroesophageal Adenocarcinoma: A Phase 2 Clinical Trial.

Radiation oncology (London, England), 2014-01-01

Stereotactic body radiotherapy with or without external beam radiation as treatment for organ confined high-risk prostate carcinoma: a six year study.

International journal of radiation oncology, biology, physics, 1980-02

An evaluation of split-course irradiation for pelvic malignancies.

Related Topics in COVID-19